HiFD`JxPBLbdTljjZDp@ en es it fr

HiFD`JxPBLbdTljjZDp@ Brand names, HiFD`JxPBLbdTljjZDp@ Analogs

HiFD`JxPBLbdTljjZDp@ Brand Names Mixture

  • No information avaliable

HiFD`JxPBLbdTljjZDp@ Chemical_Formula


HiFD`JxPBLbdTljjZDp@ RX_link


HiFD`JxPBLbdTljjZDp@ fda sheet


HiFD`JxPBLbdTljjZDp@ msds (material safety sheet)


HiFD`JxPBLbdTljjZDp@ Synthesis Reference

No information avaliable

HiFD`JxPBLbdTljjZDp@ Molecular Weight

149.212 g/mol

HiFD`JxPBLbdTljjZDp@ Melting Point

198.5 oC

HiFD`JxPBLbdTljjZDp@ H2O Solubility

1.11E+005 mg/L

HiFD`JxPBLbdTljjZDp@ State


HiFD`JxPBLbdTljjZDp@ LogP


HiFD`JxPBLbdTljjZDp@ Dosage Forms

Capsule; Tablet

HiFD`JxPBLbdTljjZDp@ Indication

For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis

HiFD`JxPBLbdTljjZDp@ Pharmacology

Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. It works by reducing numbers of T-lymphocytes, inhibiting macrophage function, decreasing IL-1, decreasing rheumatoid factor, and preventing collagen from cross-linking. Its use in Wilson's disease, a rare genetic disorder of copper metabolism, relies on its binding to accumulated copper and elimination through urine.

HiFD`JxPBLbdTljjZDp@ Absorption

rapidly but incompletely

HiFD`JxPBLbdTljjZDp@ side effects and Toxicity

No information avaliable

HiFD`JxPBLbdTljjZDp@ Patient Information

No information avaliable

HiFD`JxPBLbdTljjZDp@ Organisms Affected

Humans and other mammals